JACOBSON PHARMA CORPORATION LIMITED


Associated tags: Research, Sale, PIC/S, GMP, The Group, JBM, Pharmaceutical industry, Health care

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia

Retrieved on: 
Wednesday, June 15, 2022
International joint venture, GMP, Health care, Jacobson, ASEAN, Health, Research, Growth, Marketing, Joint venture, JBM, Acquisition, Partnership, PIC/S, Group, Awareness, Sale, Management, Pharmaceutical industry

Indeed, a strong growth forecast is also expected in the next few years, with an average annual growth rate of over 9% in the pharmaceutical and healthcare markets in China.

Key Points: 
  • Indeed, a strong growth forecast is also expected in the next few years, with an average annual growth rate of over 9% in the pharmaceutical and healthcare markets in China.
  • Mr. Raymond Yim, Executive Director of Jacobson, said, "We are very honored to partner with Ban Loong and aspire to strengthen our foothold through the Joint Venture in Greater China and markets in Asia.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    About JBM (Healthcare) Limited (Stock Code: 2161)
    JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries.
  • JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021.

Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%

Retrieved on: 
Monday, March 14, 2022
GMP, Company, Marketing, Research, PIC/S, Mergers and acquisitions, Face, Sale, The Group, Growth, Fine chemical, Group

The above share purchase represents approximately 1.06% of the total issued share capital of the Company as at 14 March 2022.

Key Points: 
  • The above share purchase represents approximately 1.06% of the total issued share capital of the Company as at 14 March 2022.
  • Mr Sum said he might consider further increasing his shareholding in the Company subject to the applicable laws and regulations.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

Jacobson Pharma Announces FY2022 Interim Results

Retrieved on: 
Friday, November 26, 2021
Private, Federation of Public and Private Sector Employees, Health care, Company, Public, Central nervous system, Tablet, Vaccination, ADHD, Marketing, Conditional sentence, Board, Febuxostat, CNS, Department, Department of Health (Hong Kong), GMP, Public Sector Marketing, JBM, Health, D, Research, Private sector development, II, Public sector, Sale, Population, The Group, Growth, Canopy Growth, Patient, Ageing, Psoriasis, HK, EBITDA, Depreciation, Prevalence, Group, PIC/S, COVID-19, Haloperidol, Idarubicin, Tax, Private sector, Fine chemical, Pharmaceutical industry

The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).

Key Points: 
  • The Board has resolved to declare an increased interim dividend by 50% to HK1.2 cents per share for the six months ended 30 September 2021 (FY2021 Interim: HK0.8 cent).
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .

Jacobson Pharma Announces FY2021 Annual Results

Retrieved on: 
Tuesday, June 29, 2021
Life sciences, Biotechnology, Articles, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Pharma

HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .

JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited

Retrieved on: 
Monday, January 25, 2021

Upon completion of the proposed spin-off, Jacobson Pharma will hold not less than 50% of the shares of JBM Healthcare ("JBM Shares") and that JBM Healthcare will remain a subsidiary of Jacobson Pharma with its results continue to be consolidated into the accounts of Jacobson Parma.

Key Points: 
  • Upon completion of the proposed spin-off, Jacobson Pharma will hold not less than 50% of the shares of JBM Healthcare ("JBM Shares") and that JBM Healthcare will remain a subsidiary of Jacobson Pharma with its results continue to be consolidated into the accounts of Jacobson Parma.
  • Jacobson Pharma will effect a distribution in specie of a portion of its JBM Shares if the spin-off proceeds, where each qualifying shareholder of Jacobson Pharma will be entitled to one JBM Share for every eight shares of Jacobson Pharma held.
  • China Galaxy International Securities (Hong Kong) Co., Limited is the Sole Sponsor of the listing.
  • JBM Healthcare will seek to utilize such insights to capture new business opportunities and capitalize on this distribution channel.

Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited

Retrieved on: 
Friday, January 15, 2021
MSCI, Companies

As of today, the total number of issued shares of the Company ("Shares") is 1,934,221,000.

Key Points: 
  • As of today, the total number of issued shares of the Company ("Shares") is 1,934,221,000.
  • If such condition is not satisfied, the proposed spin-off will not take place and the distribution will not be made.
  • For more details, please refer to the link of announcement:
    About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading generic drug company in Hong Kong.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.

Jacobson Pharma Announces FY2021 Interim Results

Retrieved on: 
Friday, November 27, 2020

HONG KONG, Nov 27, 2020 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2020 (the "reporting period").

Key Points: 
  • HONG KONG, Nov 27, 2020 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2020 (the "reporting period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading generic drug company in Hong Kong.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2020 ACN Newswire .